Nanotherapy that prevents trained immunity and promotes tolerance
Keywords:
nanoimmunotherapy, organ transplantation, HDLAbstract
Investigators at the Icahn School of Medicine at Mount Sinai in New York, USA reported a novel nanoimmunotherapy that targets myeloid cells in vivo in the November 2018 issue of the journal Immunity. Senior authors Drs. Jordi Ochando and Willem Mulder spearheaded an extensive effort in which this nanoimmunotherapy was applied to an experimental mouse model of organ transplantation. Using a short-term regimen, long-term acceptance of the transplanted organ was achieved in the absence of serious side effects.
References
Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Pérez-Medina C, et al. Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. Immunity. 2018 Nov 20;49(5):819-828.e6.
Mulder WJM, van Leent MMT, Lameijer M, Fisher EA, Fayad ZA, Pérez-Medina C. High-Density Lipoprotein Nanobiologics for Precision Medicine. Acc Chem Res. 2018 Jan 16;51(1):127–37.
Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016 Apr 22;352(6284):aaf1098.
Lameijer M, Binderup T, van Leent MMT, Senders ML, Fay F, Malkus J, et al. Author Correction: Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering. 2018 Aug 1;2(8):623–623.
